All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 21%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 1.6% from a week ago.
Before we wrap up, we've discovered 4 warning signs for Onconova Therapeutics (2 shouldn't be ignored!) that you should be aware of.
What are the risks and opportunities for Onconova Therapeutics?
NasdaqCM:ONTX
Onconova Therapeutics
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
Rewards
Revenue is forecast to grow 13.17% per year
Risks
Earnings are forecast to decline by an average of 27% per year for the next 3 years
Makes less than USD$1m in revenue ($226K)
Does not have a meaningful market cap ($13M)
Currently unprofitable and not forecast to become profitable over the next 3 years
Share Price
Market Cap
1Y Return
Further research onOnconova Therapeutics
ValuationFinancial HealthInsider TradingManagement TeamHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.